[Chemoradiotherapy of unresectable and recurrent cholangiocarcinoma].
This study is for chemoradiotherapy of unresectable and recurrent cholangiocarcinoma (CCC).


METHODS
Between April 2005 and March 2007, 5 patients were evaluated for unresectable and recurrent CCC. All patients were performed percutaneous transhepatic biliary drainage (PTBD) and treated with chemoradiotherapy. The radiation method was an external beam radiotherapy (EBRT) and remote after loading system (RALS). The chemotherapy was 5-FU and gemcitabine by intravenous injection.


RESULTS
Three patients had unresectable and 2 had recurrent CCC. As for the side effects, 4 patients had a slight neutropenia and 1 had an uncontrollable gastric bleeding. No patient had cholangitis. The mean survival time for unresectable and recurrent CCC was 13.7 months and 17 months, respectively.


CONCLUSIONS
Our results indicated that chemoradiotherapy had been consistent with efficacy in patients with unresectable and recurrent CCC.
Horiuchi
Hiroyuki
H
Dept. of Surgery, Ohmuta Municipal General Hospital.
Ureshino
Mitsutoshi
M
Yoshimura
Fumihiro
F
Matono
Satoru
S
Fukumitsu
Takamasa
T
Kishimoto
Yukiya
Y
Sasahara
Hiroko
H
Kubota
Masahiro
M
Takada
Kazuhide
K
Noguchi
Kazunori
K
Maruyama
Yuuichirou
Y
Kawahara
Ryuichi
R
Ishikawa
Hiroto
H
Hisaka
Tohru
T
Sakai
Takenori
T
Uchida
Shinji
S
Kinoshita
Hisafumi
H
Shirouzu
Kazuo
K
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D018281:Cholangiocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*
D014408:Biomarkers, Tumor